Rigosertib - Onconova Therapeutics

Drug Profile

Rigosertib - Onconova Therapeutics

Alternative Names: Estybon; Novonex; ON-01910; ON-01910-sodium; ON-01910.Na; ON-01910Na; Rigosertib sodium; SyB C-1101; SyB L-1101

Latest Information Update: 24 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Onconova Therapeutics
  • Developer M. D. Anderson Cancer Center; Onconova Therapeutics; SymBio Pharmaceuticals
  • Class Amino acids; Antineoplastics; Small molecules; Sulfones
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Myelodysplastic syndromes
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Acute myeloid leukaemia; Myelofibrosis; Solid tumours
  • Phase I Head and neck cancer
  • No development reported Chronic lymphocytic leukaemia; Ovarian cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Squamous cell cancer

Most Recent Events

  • 17 Oct 2018 Onconova Therapeutics has patent protection for rigosertib in the US
  • 22 Aug 2018 Onconova Therapeutics completes enrolment in its phase I/II trial for Myelodysplastic syndrome (MDS) in the USA and France
  • 14 Aug 2018 Onconova Therapeutics plans a phase III trial for Myelodysplastic Syndromes (Combination therapy) in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top